CVKD
Cadrenal Therapeutics, Inc.

5,279
Mkt Cap
$21.15M
Volume
18,001.00
52W High
$22.90
52W Low
$8.74
PE Ratio
-1.27
CVKD Fundamentals
Price
$10.04
Prev Close
$10.19
Open
$10.26
50D MA
$13.07
Beta
0.98
Avg. Volume
25,589.22
EPS (Annual)
-$8.73
P/B
7.67
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Why the underdog mindset could be your business superpower
You can catch Warrior Money on Apple Podcasts, Spotify, Amazon Music, or wherever you get your podcasts. What does it take to go from refugee kid to Marine pilot, biotech CEO, and author? On this...
Yahoo! Finance-YouTube·7d ago
News Placeholder
More News
News Placeholder
Cadrenal Therapeutics, Inc.
CVKD: Acquires Factor XIa Inhibitors
Zacks·17d ago
News Placeholder
Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million
The company said that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings.
Stocktwits·2mo ago
News Placeholder
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new...
Business Wire·10mo ago
News Placeholder
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, leading with tecarfarin, a new Vitamin K...
Business Wire·10mo ago
News Placeholder
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), today announced that Chairman and Chief Executive Officer, Quang X. Pham, will participate in a webcasted fireside chat at the Lytham Partners 2025...
Business Wire·11mo ago
News Placeholder
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) today recapped its 2024 milestones and highlighted a clear path forward to develop the investigational drug tecarfarin as a superior and safer chronic...
Business Wire·11mo ago
News Placeholder
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January...
Business Wire·11mo ago
News Placeholder
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook PR...
PR Newswire·1y ago
News Placeholder
CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE
CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE PR Newswire PONTE VEDRA, Fla., Nov. 7, 2024 PONTE VEDRA, Fla., Nov. 7, 2024...
PR Newswire·1y ago

Latest CVKD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.